Response to therapy
prostatic tissue tumors, skeletal lesions, visceral disease, tumor
DISEASE PROGRESSION, TUMOR
At inclusion, 17/18 participants had skeletal lesions visible on scintigraphy, while 16/18 patients had evaluable visceral disease in the form of prostatic tissue tumors. Several patients had PET-positive lymph nodes. Long-term (> 46 weeks) clinical benefit were achieved by 6/18 (33%) participants. Out of 12, 1 patient who progressed was not followed radiologically due to rapid disease progression and malaise (Fig. When changes were measured two and six weeks after CryoIT, differences were observed between participants who had progressed radiologically and those with clinical benefit 22 weeks after treatment (PSA (Clinical, laboratory and radiological outcomes. All patients with pre-treatment CTCs showed either transient CTC decreases which lasted months for several patients (pre-treatment CTC ≥ 5/7.5, Changes in circulating tumor cells (CTC) and T cell receptor (TCR) clonotypes. Two weeks after the intervention, CTC numbers were available for 12/18 (67%). The CTC response analyses identified longer PFS for those with complete disappearance of CTCs (Figure Health-related quality-of-life measurements. Time in weeks since trial inclusion (baseline) is illustrated along the x-axis of all plots. 